{
    "address1": "9390 Towne Centre Drive",
    "address2": "Suite 200",
    "city": "San Diego",
    "state": "CA",
    "zip": "92121",
    "country": "United States",
    "phone": "858 779 3100",
    "website": "https://poseida.com",
    "industry": "Biotechnology",
    "industryDisp": "Biotechnology",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.",
    "fullTimeEmployees": 348,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Mr. Mark J. Gergen J.D.",
            "age": 59,
            "title": "Pres, CEO & Chairman",
            "yearBorn": 1963,
            "fiscalYear": 2022,
            "totalPay": 920740,
            "exercisedValue": 0,
            "unexercisedValue": 817228
        },
        {
            "maxAge": 1,
            "name": "Mr. Harry J. Leonhardt Esq., J.D.",
            "age": 65,
            "title": "Gen. Counsel, Chief Compliance Officer & Corp. Sec.",
            "yearBorn": 1957,
            "fiscalYear": 2022,
            "totalPay": 630233,
            "exercisedValue": 0,
            "unexercisedValue": 25579
        },
        {
            "maxAge": 1,
            "name": "Mr. Brent  Warner",
            "age": 38,
            "title": "Pres of Gene Therapy",
            "yearBorn": 1984,
            "fiscalYear": 2022,
            "totalPay": 835929,
            "exercisedValue": 0,
            "unexercisedValue": 151938
        },
        {
            "maxAge": 1,
            "name": "Ms. Johanna M. Mylet CPA",
            "age": 35,
            "title": "Chief Financial Officer",
            "yearBorn": 1987,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Loren  Wagner",
            "title": "Sr. VP of Global Operations",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Kristin  Martin",
            "title": "Chief People & Admin. Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Sarah  Thailing",
            "title": "Sr. Director of Corp. Communications & IR",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Devon J. Shedlock Ph.D.",
            "title": "Chief Scientific Officer of Cell Therapy",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Lisa  Portale",
            "title": "Sr. VP of Regulatory Affairs",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Jeffrey  W. Winkelman J.D., Ph.D.",
            "title": "Sr. VP & Chief Patent Counsel",
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 4,
    "previousClose": 2.35,
    "open": 2.37,
    "dayLow": 2.08,
    "dayHigh": 2.38,
    "regularMarketPreviousClose": 2.35,
    "regularMarketOpen": 2.37,
    "regularMarketDayLow": 2.08,
    "regularMarketDayHigh": 2.38,
    "payoutRatio": 0.0,
    "beta": 0.121292,
    "forwardPE": -1.2883435,
    "volume": 841834,
    "regularMarketVolume": 841834,
    "averageVolume": 1205432,
    "averageVolume10days": 565620,
    "averageDailyVolume10Day": 565620,
    "bid": 2.05,
    "ask": 2.19,
    "bidSize": 800,
    "askSize": 3200,
    "marketCap": 199728672,
    "fiftyTwoWeekLow": 1.54,
    "fiftyTwoWeekHigh": 8.82,
    "priceToSalesTrailing12Months": 1.274487,
    "fiftyDayAverage": 2.0804,
    "twoHundredDayAverage": 3.9698,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "enterpriseValue": 54999016,
    "profitMargins": -0.1864,
    "floatShares": 48782586,
    "sharesOutstanding": 95108896,
    "sharesShort": 3786594,
    "sharesShortPriorMonth": 4134514,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.0398,
    "heldPercentInsiders": 0.28260002,
    "heldPercentInstitutions": 0.52318,
    "shortRatio": 2.71,
    "shortPercentOfFloat": 0.061100002,
    "impliedSharesOutstanding": 95108896,
    "bookValue": 1.557,
    "priceToBook": 1.3487475,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "netIncomeToCommon": -29212000,
    "trailingEps": -0.04,
    "forwardEps": -1.63,
    "pegRatio": -0.6,
    "enterpriseToRevenue": 0.351,
    "enterpriseToEbitda": -2.353,
    "52WeekChange": -0.36555892,
    "SandP52WeekChange": 0.09306288,
    "exchange": "NMS",
    "quoteType": "EQUITY",
    "symbol": "PSTX",
    "underlyingSymbol": "PSTX",
    "shortName": "Poseida Therapeutics, Inc.",
    "longName": "Poseida Therapeutics, Inc.",
    "firstTradeDateEpochUtc": 1594387800,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "291e20e1-54d3-33de-96cd-b23bf8be3533",
    "messageBoardId": "finmb_302863260",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 2.1,
    "targetHighPrice": 15.0,
    "targetLowPrice": 8.0,
    "targetMeanPrice": 11.8,
    "targetMedianPrice": 12.0,
    "recommendationMean": 1.5,
    "recommendationKey": "strong_buy",
    "numberOfAnalystOpinions": 5,
    "totalCash": 214606000,
    "totalCashPerShare": 2.469,
    "ebitda": -23375000,
    "totalDebt": 87081000,
    "quickRatio": 4.54,
    "currentRatio": 4.614,
    "totalRevenue": 156712992,
    "debtToEquity": 64.361,
    "revenuePerShare": 1.868,
    "returnOnAssets": -0.074,
    "returnOnEquity": -0.29052,
    "grossProfits": -22407000,
    "freeCashflow": 1719125,
    "operatingCashflow": -7030000,
    "revenueGrowth": 6.412,
    "grossMargins": 0.0174,
    "ebitdaMargins": -0.14916,
    "operatingMargins": -0.18385,
    "financialCurrency": "USD",
    "trailingPegRatio": null,
    "parent_etfs": [
        "GNOM"
    ]
}